Epicutaneous 1-Chloro-2, 4-Dinitrobenzene (DNCB) Patch in HIV Infection.
This study has been completed.
Information provided by:
NIH AIDS Clinical Trials Information Service
First received: November 2, 1999
Last updated: June 23, 2005
Last verified: January 1999
To evaluate the efficacy of dinitrochlorobenzene (DNCB) in patients with early HIV infection by monitoring immunologic parameters and serum HIV RNA. To facilitate the understanding of possible alterations in the immunological status of the HIV+ patient cohort.
||Endpoint Classification: Efficacy Study
Primary Purpose: Treatment
||Epicutaneous 1-Chloro-2, 4-Dinitrobenzene (DNCB) Patch in HIV Infection.
|Ages Eligible for Study:
||18 Years to 55 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Patients must have:
- EITHER HIV negative or documented HIV+ by both the ELISA and Western blot tests.
For HIV+ patients:
- Patients must fail to meet the AIDS-defining criteria.
- CD4 lymphocyte count between 200 - 500 cells/mm3.
Patients with obvious ultra violet(UV)-irradiated skin damage in the treatment sites.
- Patients who are likely to commence antiretrovirals within the 6-month study period.
- Patients using other immunomodulator therapies or other alternative therapies.
- Patients likely to require chemotherapy during the course of the study.
- Patients who are likely to require significant UV light exposure during the study period.
- Patients who are likely to require radiation therapy during the course of the study.
- Prior exposure to DNCB.
- Patients who have used antiretroviral medications within the previous 3 months.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002175
|Queen Emma Clinics / The Queen's Med Ctr
|Honolulu, Hawaii, United States, 96813 |
The Honolulu Medical Group
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||November 2, 1999
||June 23, 2005
||United States: Food and Drug Administration
Keywords provided by NIH AIDS Clinical Trials Information Service:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on November 20, 2014
Acquired Immunodeficiency Syndrome
Immune System Diseases
Immunologic Deficiency Syndromes
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases